Clinical Trial Detail

NCT ID NCT03979508
Title Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic
Indications

triple-receptor negative breast cancer

Therapies

Abemaciclib

Age Groups: senior adult

No variant requirements are available.